Herpes virus infections amongst moderate to severe atopic dermatitis patients treated with baricitinib: an integrated analysis of phase 3 trials

被引：0
|
作者：
Werfel, T. [1 ]
Irvine, A. D. [2 ]
Bangert, C. [3 ]
Seneschal, J. [4 ]
Grond, S. [5 ]
Cardillo, T. [5 ]
Brinker, D. [5 ]
Zhong, J. [6 ]
Riedl, E. [5 ]
Wollenberg, A. [7 ]
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Trinity Coll Dublin, Dublin, Ireland
[3] Med Univ Vienna, Vienna, Austria
[4] Hop St Andre, Bordeaux, France
[5] Eli Lilly & Co, Indianapolis, IN USA
[6] IQVIA, Durham, NC USA
[7] Ludwig Maximillian Univ, Munich, Germany
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2021年 / 141卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
084
引用
收藏
页码：S162 / S162
页数：1
相关论文
共 50 条
  • [21] The effect of baricitinib on daily and workplace activity from phase 3 trials BREEZE-AD1 and BREEZE-AD2 in adult patients with moderate to severe atopic dermatitis
    Eichenfield, Lawrence F.
    Silverberg, Jonathan I.
    Carrascosa, Jose-Manuel
    Rubel, Diana
    Watts, Steven
    Casillas, Marta
    DeLozier, Amy M.
    Pierce, Evangeline
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB140 - AB140
  • [22] Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
    Radi, Giulia
    Simonetti, Oriana
    Rizzetto, Giulio
    Diotallevi, Federico
    Molinelli, Elisa
    Offidani, Annamaria
    HEALTHCARE, 2021, 9 (11)
  • [23] Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
    Gold, Linda Stein
    Thaci, Diamant
    Thyssen, Jacob P.
    Gooderham, Melinda
    Laquer, Vivian
    Moore, Angela
    Natalie, Chitra R.
    Zhao, Fangyi
    Meskimen, Eric
    Elmaraghy, Hany
    Montmayeur, Sonia
    Gallo, Gaia
    Jimenez, Gemma
    de Bruin-Weller, Marjolein
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (04) : 595 - 607
  • [24] Treatment of moderate-to-severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry
    Traidl, Stephan
    Heinrich, Luise
    Siegels, Doreen
    Heratizadeh, Annice
    Kind, Barbara
    Haufe, Eva
    Abraham, Susanne
    Schaefer, Thomas
    Augustin, Matthias
    Harder, Inken
    Pinter, Andreas
    Schaekel, Knut
    Wollenberg, Andreas
    Ertner, Konstantin
    Ramaker-Brunke, Jutta
    Bong, Anne
    Quist, Sven
    Gorriahn-Maiterth, Hannah
    Schenck, Florian
    Sticherling, Michael
    Effendy, Isaak
    Schwarz, Beate
    Handrick, Christiane
    Asmussen, Andrea
    Weidinger, Stephan
    Schmitt, Jochen
    Werfel, Thomas
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024,
  • [25] Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
    Linda Stein Gold
    Diamant Thaçi
    Jacob P. Thyssen
    Melinda Gooderham
    Vivian Laquer
    Angela Moore
    Chitra R. Natalie
    Fangyi Zhao
    Eric Meskimen
    Hany Elmaraghy
    Sonia Montmayeur
    Gaia Gallo
    Gemma Jimenez
    Marjolein de Bruin-Weller
    American Journal of Clinical Dermatology, 2023, 24 : 595 - 607
  • [26] Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB72 - AB72
  • [27] Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
    Buhl, Timo
    Rosmarin, David
    Serra-Baldrich, Esther
    Fernandez-Penas, Pablo
    Igarashi, Atsuyuki
    Konstantinou, Maria Polina
    Chen, Sherry
    Lu, Na
    Pierce, Evangeline
    Casillas, Marta
    DERMATOLOGY AND THERAPY, 2021, 11 (03) : 971 - 982
  • [28] Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    Bangert, Christine
    Irvine, Alan D.
    Weidinger, Stephan
    Johnson, Susan
    Lazariciu, Irina
    Koppensteiner, Herwig
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 77
  • [29] Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
    Timo Buhl
    David Rosmarin
    Esther Serra-Baldrich
    Pablo Fernandez-Peñas
    Atsuyuki Igarashi
    Maria Polina Konstantinou
    Sherry Chen
    Na Lu
    Evangeline Pierce
    Marta Casillas
    Dermatology and Therapy, 2021, 11 : 971 - 982
  • [30] Summary of efficacy, impact on work productivity and activity, and safety of baricitinib in moderate-to-severe atopic dermatitis from two monotherapy phase III trials
    Wollenberg, A.
    Carrascosa, J. Manuel
    Lacour, J. -P.
    Reich, K.
    Eichenfield, L.
    Rubel, D.
    Cardillo, T.
    Gittens, B.
    Grond, S.
    Augustin, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 : 66 - 66
12345